Genprex, Inc.(@genprex) 's Twitter Profile Photo

Genprex recently announced we have added multiple clinical trial sites for the Acclaim-3 clinical study of Reqorsa® Immunogene Therapy in combination with Genentech’s Tecentriq® to treat patients with ES . More details: ow.ly/NRNV50RtHBl $GNPX

Genprex recently announced we have added multiple clinical trial sites for the Acclaim-3 clinical study of Reqorsa® Immunogene Therapy in combination with Genentech’s Tecentriq® to treat patients with ES #SCLC. More details: ow.ly/NRNV50RtHBl $GNPX
account_circle
Heal Me Plus - Medical Tourism(@Healmeplus) 's Twitter Profile Photo

There are mainly two types of Lung Cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC). SCLC is less common than NSCLC but is more aggressive and typically requires different treatment approaches, such as chemotherapy and radiation therapy.

account_circle
sclc_uk(@sclc_uk) 's Twitter Profile Photo

We’re soliciting for sponsorship for our year6 pupils; who will be passing out Jun/Jul 2024. They are currently beneficiaries of the SCLC initiative but as it stands, there’s no hope for high school for them. We plead with everyone seeing this and is capable to help to pls HELP.

account_circle
Byung-June Park(@onco_park) 's Twitter Profile Photo

Scientific Rationale Behind Tarlatamab's Clinical Development in Early-Stage SCLC?

Amgen has drawn inspiration from the ECOG-ACRIN E1910 trial with blinatumomab to expand tarlatamab into earlier stages of SCLC clinical development. Blinatumomab has effectively converted…

Scientific Rationale Behind Tarlatamab's Clinical Development in Early-Stage SCLC? 

Amgen has drawn inspiration from the ECOG-ACRIN E1910 trial with blinatumomab to expand tarlatamab into earlier stages of SCLC clinical development. Blinatumomab has effectively converted…
account_circle
Mike Kareta & Lab(@kareta_mike) 's Twitter Profile Photo

Very excited to have Robert Szczepaniak-Sloane present his work in the Kareta Lab about regulators of HLA repression in at the SCLC Consortium this past week, hosted at the National Cancer Institute. Sanford Research

Very excited to have Robert Szczepaniak-Sloane present his work in the Kareta Lab about regulators of HLA repression in #SCLC at the SCLC Consortium this past week, hosted at the @theNCI. @SanfordResearch
account_circle
AlFaroNoticias(@AlfaroNoticiasD) 's Twitter Profile Photo

Aspirantes a la alcaldía de SCLC se unen en pacto por la conservación de humedales y seguridad, También se comprometieron a abordar los desafíos de seguridad y garantizar el suministro de agua potable para las comunidades del sur de la ciudad.
alfaronoticias.com.mx/aspirantes-a-l…

Aspirantes a la alcaldía de SCLC se unen en pacto por la conservación de humedales y seguridad, También se comprometieron a abordar los desafíos de seguridad y garantizar el suministro de agua potable para las comunidades del sur de la ciudad.
alfaronoticias.com.mx/aspirantes-a-l…
account_circle
Sacramento Cultural & Linguistic Center(@TeamSclc) 's Twitter Profile Photo

As the countdown to the Big Day of Giving on May 2nd continues, with only 4 days left, we are delighted to highlight our team member Muang Saechao, whose dedication as a Mien/Lao Cultural interpreter at SCLC has illuminated our community for over two decades.

As the countdown to the Big Day of Giving on May 2nd continues, with only 4 days left, we are delighted to highlight our team member Muang Saechao, whose dedication as a Mien/Lao Cultural interpreter at SCLC has illuminated our community for over two decades.  #BigDayOfGiving
account_circle
Byung-June Park(@onco_park) 's Twitter Profile Photo

Paolo Tarantino HS-20093 (B7-H3), which incorporates an unclosed topoisomerase inhibitor, showed a response in SCLC patients pretreated with irinotecan.

@PTarantinoMD HS-20093 (B7-H3), which incorporates an unclosed topoisomerase inhibitor, showed a response in SCLC patients pretreated with irinotecan.
account_circle
Lauren Averett Byers, MD(@LaurenByersMD) 's Twitter Profile Photo

That feeling when the #1, #2, and #7 most impactful Small Cell Lung Cancer publications from National Cancer Institute SCLC Consortium were led by your mentees and Byers Lab Group Leader (out of 200+ publications). Congratulations to Drs. Carl Gay, Triparna Sen (Sen-Lab), and Dr. Allison Stewart.

That feeling when the #1, #2, and #7 most impactful Small Cell Lung Cancer publications from @theNCI SCLC Consortium were led by your mentees  and Byers Lab Group Leader (out of 200+ publications). Congratulations to Drs. Carl Gay, @triparnasen, and Dr. Allison Stewart. #lcsm
account_circle
Lauren Averett Byers, MD(@LaurenByersMD) 's Twitter Profile Photo

Thank you Peter Ujhazy Peter Ujhazy, National Cancer Institute and all of the Small Cell Lung Cancer Consortium members for a great meeting. Amazing to see the progress over 10 years since we first met to make a plan to accelerate progress for patients with SCLC.

Thank you @PTRUJH Peter Ujhazy, @theNCI and all of the Small Cell Lung Cancer Consortium members for a great #SCLC #LCSM meeting. Amazing to see the progress over 10 years since we first met to make a plan to accelerate progress for patients with SCLC.
account_circle
Yonghao Yu Lab - Hiring now!(@yu_yonghao) 's Twitter Profile Photo

PARP1 as a therapeutic target for BRCAmut cancers has been well established. However, PARPi are increasingly being used for cancers without BRCA mutations. In this new publication, we sought to understand the mechanism of action of PARPi in SCLC. science.org/doi/full/10.11…

account_circle
Oye Chiapas(@Oye_Chiapas) 's Twitter Profile Photo

Improcedentes registros de candidaturas a las alcaldías de SCLC y Catazajá, de Chiapas Unido
oyechiapas.com/estado/tuxtla-…

Improcedentes registros de candidaturas a las alcaldías de SCLC y Catazajá, de Chiapas Unido
oyechiapas.com/estado/tuxtla-…
account_circle